Shuttle Pharmaceuticals (SHPH) News Today $0.17 0.00 (-2.74%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.17 0.00 (0.00%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SHPH Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deShuttle Pharma Provides Corporate UpdateMay 15, 2025 | globenewswire.comShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comShuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025April 24, 2025 | nasdaq.comShuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 21, 2025 | globenewswire.comShuttle Pharmaceuticals files provisional patent application with USPTOApril 12, 2025 | markets.businessinsider.comShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApril 10, 2025 | globenewswire.comShuttle Pharmaceuticals Appoints New Interim CEO and CSOMarch 31, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical TrialMarch 13, 2025 | quiverquant.comShuttle Pharma Announces Closing of $5.75 Million Underwritten OfferingMarch 13, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business ActivitiesMarch 12, 2025 | finanznachrichten.deShuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEOMarch 12, 2025 | markets.businessinsider.comShuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offeringMarch 12, 2025 | markets.businessinsider.comShuttle Pharma Announces Pricing of $5.75 Million Underwritten OfferingMarch 12, 2025 | globenewswire.comShuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business ActivitiesMarch 12, 2025 | globenewswire.comShuttle Pharmaceuticals Enters Revolving Loan AgreementFebruary 28, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate Update and Reports 2024 ResultsFebruary 26, 2025 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc. Reports Progress on Phase 2 Trial and Diagnostic Advancements in Annual UpdateFebruary 26, 2025 | quiverquant.comShuttle Pharma Provides Corporate Update and Reports 2024 ResultsFebruary 26, 2025 | globenewswire.comHere’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage UniverseFebruary 12, 2025 | msn.comShuttle Pharmaceuticals expands glioblastoma trialJanuary 29, 2025 | msn.comShuttle reaches milestone in enrollment for Phase 2 trial of RopidoxuridineJanuary 22, 2025 | markets.businessinsider.comShuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaJanuary 22, 2025 | markets.businessinsider.comShuttle Pharma hits 25% mark in glioblastoma trialJanuary 22, 2025 | msn.comShuttle Pharmaceuticals CEO Anatoly Dritschilo to Speak at Lytham Partners 2025 Investor Healthcare SummitJanuary 7, 2025 | quiverquant.comShuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025January 7, 2025 | globenewswire.comShuttle Pharmaceuticals enters into sponsored research agreement with UCSFDecember 21, 2024 | markets.businessinsider.comShuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development ProgramDecember 19, 2024 | markets.businessinsider.comShuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First PatientNovember 26, 2024 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Third Quarter 2024 Corporate UpdateNovember 15, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc. Advances Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma TreatmentNovember 13, 2024 | quiverquant.comShuttle Pharma Provides Third Quarter 2024 Corporate UpdateNovember 13, 2024 | globenewswire.comShuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination NewsNovember 2, 2024 | msn.comMicro Cap Company Is Soaring On Phase 2 Trial UpdateOctober 31, 2024 | theglobeandmail.com“Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs”October 30, 2024 | theglobeandmail.comShuttle Pharmaceuticals doses first patients in Phase 2 trial of RopidoxuridineOctober 30, 2024 | markets.businessinsider.comShuttle Pharmaceuticals (NASDAQ:SHPH) Stock, Short Interest ReportOctober 30, 2024 | benzinga.comShuttle Pharma Pays Off Senior Secured Convertible NoteOctober 30, 2024 | finance.yahoo.comShuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaOctober 30, 2024 | finance.yahoo.comShuttle Pharmaceuticals (NASDAQ:SHPH) Stock Quotes, Forecast and News SummaryOctober 30, 2024 | benzinga.comShuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq RulesOctober 29, 2024 | globenewswire.comShuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site UpdateOctober 29, 2024 | marketwatch.comShuttle Pharma Updates On Clinical Trial Site; Stock SurgesOctober 29, 2024 | markets.businessinsider.comShuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaOctober 28, 2024 | globenewswire.comShuttle Pharma advances glioblastoma treatment trialSeptember 19, 2024 | uk.investing.comShuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaSeptember 16, 2024 | globenewswire.comShuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug StudySeptember 5, 2024 | marketwatch.comWhy Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile TodaySeptember 5, 2024 | msn.comShuttle Pharma Provides Second Quarter 2024 Corporate UpdateSeptember 4, 2024 | globenewswire.comShuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 28, 2024 | markets.businessinsider.com Get Shuttle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter. Email Address SHPH Media Mentions By Week SHPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SHPH News Sentiment▼0.000.75▲Average Medical News Sentiment SHPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SHPH Articles This Week▼01▲SHPH Articles Average Week Get Shuttle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNOA News ENSC News APM News CNSP News EVOK News DRMA News JAGX News ONCO News LIXT News CDT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SHPH) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shuttle Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shuttle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.